ArticleRevista da Associacao Medica Brasileira (1992)2026
Gastrin-releasing peptide, neuromedin B, and symptom severity in adult attention-deficit hyperactivity disorder.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAttention-deficit hyperactivity disorder is a neurodevelopmental disorder associated with metabolic and neuropeptidergic processes. Gastrin-releasing peptide and neuromedin B, which are bombesin-like peptides, have been studied only to a limited extent in adult attention-deficit hyperactivity disorder, despite their role in energy homeostasis and central nervous system function. The aim of this study was to evaluate gastrin-releasing peptide and neuromedin B levels in untreated adult attention-deficit hyperactivity disorder patients and to examine their relationship with clinical symptom severity.
methodsThis cross-sectional study included 55 untreated adult attention-deficit hyperactivity disorder patients and 32 healthy controls. Attention-deficit hyperactivity disorder diagnoses were confirmed using SCID-5/CV and DIVA 2.0, and symptom severity was assessed using the Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale. Gastrin-releasing peptide and neuromedin B levels in fasting serum were measured using the ELISA method. Group comparisons, Pearson correlations, hierarchical regression, and receiver operating characteristic analyses were performed.
resultsGastrin-releasing peptide (22.83±24.18 pg/mL) and neuromedin B (1.83±2.86 pg/mL) levels were significantly lower in the attention-deficit hyperactivity disorder group compared to the control group (p=0.004 and p=0.037, respectively). Gastrin-releasing peptide and neuromedin B levels were negatively correlated with Attention-Deficit Hyperactivity Disorder Self-Report Scale total and subscale scores (p<0.001 for all). In regression analyses, gastrin-releasing peptide was an independent predictor of Attention-Deficit Hyperactivity Disorder Self-Report Scale total score (β=-0.642, p=0.024). In receiver operating characteristic analyses, gastrin-releasing peptide (AUC=0.746) and neuromedin B (AUC=0.719) showed significant performance in distinguishing attention-deficit hyperactivity disorder.
conclusionThe findings suggest that gastrin-releasing peptide, in particular, may be associated with clinical symptom severity in adult attention-deficit hyperactivity disorder and is a potential biomarker candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.